Literature DB >> 33829269

Should women receive luteal support following natural cycle frozen embryo transfer? A systematic review and meta-analysis.

Yossi Mizrachi1, Eran Horowitz1, Hadas Ganer Herman1, Jacob Farhi1, Arieh Raziel1, Ariel Weissman1.   

Abstract

BACKGROUND: Spontaneous ovulation during a natural menstrual cycle is frequently used for timing frozen embryo transfer (FET). Nevertheless, it remains unclear whether or not women should receive luteal phase support (LPS) following natural cycle frozen embryo transfer (NC-FET). OBJECTIVE AND RATIONALE: The aim of this systematic review and meta-analysis was to study whether the administration of LPS improves the reproductive outcome following NC-FET. SEARCH
METHODS: We conducted a systematic search of the literature published in Medline/PubMed, Embase and the Cochrane Library, from January 2000 until December 2020. We included all original English, peer-reviewed articles, irrespective of the study design. The search strategy included keywords related to NC-FET and luteal phase support. Studies reporting the results of artificial or stimulated FET cycles were excluded. OUTCOMES: Our systematic search generated 416 records. After screening, eight studies were included in the review and seven studies were included in the meta-analysis. Two studies (n = 858) used hCG and six studies (n = 1507) used progesterone for luteal support. Four studies were randomised controlled trials (RCTs), whereas the other four were historic cohort studies. In a meta-analysis using a random effects model, hCG administration for LPS did not increase the clinical pregnancy rate (CPR) (two studies, odds ratio (OR) 0.85, 95% CI 0.64-1.14). On the other hand, progesterone LPS was associated with a higher CPR (five studies, OR 1.48, 95% CI 1.14-1.94), and a higher live birth rate (LBR) (three studies, OR 1.67, 95% CI 1.19-2.36). The association between progesterone LPS and the LBR remained significant after excluding non-randomised studies. WIDER IMPLICATIONS: The available evidence indicates that progesterone administration for LPS is beneficial following NC-FET. There is no evidence to support the administration of hCG for LPS in these cases. Additional large RCTs are necessary to improve the quality of evidence and validate our findings.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  FET; IVF; frozen; hCG; luteal support; natural cycle; progesterone

Mesh:

Substances:

Year:  2021        PMID: 33829269     DOI: 10.1093/humupd/dmab011

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  4 in total

1.  Vaginal progesterone as luteal phase support in natural cycle frozen-thawed embryo transfer (ProFET): protocol for a multicentre, open-label, randomised controlled trial.

Authors:  Caroline Stadelmann; Christina Bergh; Mats Brännström; Kristbjörg Heiður Olsen; Ali Khatibi; Margareta Kitlinski; Susanne Liffner; Eva Lundborg; Kenny A Rodriguez-Wallberg; Annika Strandell; Göran Westlander; Gabriella Widlund; Åsa Magnusson
Journal:  BMJ Open       Date:  2022-07-08       Impact factor: 3.006

2.  Impact of Luteinized Unruptured Follicles on Clinical Outcomes of Natural Cycles for Frozen/Thawed Blastocyst Transfer.

Authors:  Song Li; Lokwan Liu; Tian Meng; Benyu Miao; Mingna Sun; Canquan Zhou; Yanwen Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-21       Impact factor: 5.555

3.  Clinical Overview of Luteal Deficiency in Dairy Cattle.

Authors:  Fernando López-Gatius; Irina Garcia-Ispierto
Journal:  Animals (Basel)       Date:  2022-07-22       Impact factor: 3.231

4.  Progesterone supplementation in natural cycles improves live birth rates after embryo transfer of frozen-thawed embryos-a randomized controlled trial.

Authors:  K Wånggren; M Dahlgren Granbom; S I Iliadis; J Gudmundsson; A Stavreus-Evers
Journal:  Hum Reprod       Date:  2022-09-30       Impact factor: 6.353

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.